ArticleMalaria journal2013
Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
Article in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.The Journal of infectious diseases · 2018Trial
- Zoonotic Parasite Nanovaccines: Progress, Challenges, and Future Perspectives.Integrative zoology · 2026Review
- A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.Nature microbiology · 2026Article
- Elicitation of liver-stage immunity by nanoparticle immunogens displaying P. falciparum CSP-derived antigens.NPJ vaccines · 2025Article
- Review
- Immunogenicity, Efficacy, and Safety of a Novel Synthetic Microparticle Pre-Erythrocytic Malaria Vaccine in Multiple Host Species.Vaccines · 2023Article
- Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model.NPJ vaccines · 2023Article
- mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum.NPJ vaccines · 2022Article
- Sporozoite motility as a quantitative readout for anti-CSP antibody inhibition.Scientific reports · 2022Article
- Nano toolbox in immune modulation and nanovaccines.Trends in biotechnology · 2022Review
- Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice.NPJ vaccines · 2021Article
- A chemokine-fusion vaccine targeting immature dendritic cells elicits elevated antibody responses to malaria sporozoites in infant macaques.Scientific reports · 2021Article
- Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice.Scientific reports · 2020Article
- Complement in malaria: immune evasion strategies and role in protective immunity.FEBS letters · 2020Review
- Advancements in prophylactic and therapeutic nanovaccines.Acta biomaterialia · 2020Review
- Complement in malaria immunity and vaccines.Immunological reviews · 2020Review
- A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation.Journal of immunological methods · 2019Article
- A Modular Vaccine Platform Combining Self-Assembled Peptide Cages and Immunogenic Peptides.Advanced functional materials · 2019Article
- Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning.Scientific reports · 2018Article
- Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children.BMC medicine · 2018Article
Corrections and comments
- Erratum issuedZou, Xiaoyan [added]; Gerbasi, Vincent R [added]
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundA lack of defined correlates of immunity for malaria, combined with the inability to induce long-lived sterile immune responses in a human host, demonstrate a need for improved understanding of potentially protective immune mechanisms for enhanced vaccine efficacy. Protective sterile immunity (>90%) against the Plasmodium falciparum circumsporozoite protein (CSP) has been achieved using a transgenically modified Plasmodium berghei sporozoite (Tg-Pb/PfCSP) and a self-assembling protein nanoparticle (SAPN) vaccine presenting CSP epitopes (PfCSP-SAPN). Here, several possible mechanisms involved in the independently protective humoral and cellular responses induced following SAPN immunization are described.
methodsInbred mice were vaccinated with PfCSP-SAPN in PBS. Serum antibodies were harvested and effects on P. falciparum sporozoites mobility and integrity were examined using phase contrast microscopy. The functionality of SAPN-induced antibodies on inhibition of sporozoite invasion and growth within primary human hepatocytes was also examined. The internal processing of SAPN by bone marrow-derived dendritic cells (BMDDC), using organelle-specific, fluorescent-tagged antibody or gold-encapsulated SAPN, was observed using confocal or electron microscopy, respectively.
resultsThe results of this work demonstrate that PfCSP-SAPN induces epitope-specific antibody titers, predominantly of the Th2 isotype IgG1, and that serum antibodies from PfCSP-SAPN-immunized mice appear to target P. falciparum sporozoites via the classical pathway of complement. This results in sporozoite death as indicated by cessation of motility and the circumsporozoite precipitation reaction. Moreover, PfCSP-SAPN-induced antibodies are able to inhibit wild-type P. falciparum sporozoite invasion and growth within cultured primary human hepatocytes. In addition, the observation that PfCSP-SAPN are processed (and presented) to the immune system by dendritic cells in a slow and continuous fashion via transporter associated with antigen processing (TAP) recruitment to the early endosome (EE), and have partially delayed processing through the endoplasmic reticulum, has the potential to induce the long-lived, effector memory CD8+ T-cells as described previously.
conclusionThis paper describes the examination of humoral and cellular immune mechanisms induced by PfCSP-SAPN vaccination which result in sterile host protection against a transgenic P. berghei malaria sporozoite expressing the P. falciparum CSP, and which significantly inhibits native P. falciparum sporozoites from invading and developing within cultured human hepatocytes. These results may indicate the type and mode of action of protective antibodies needed to control P. falciparum sporozoites from infecting humans as well as a potential mechanism of induction of protective long-lived effector memory CD8+ T-cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.